Classify Anti-Malarial Drugs. Write briefly about the MoA, Adverse Effects & Therapeutic Uses of Artemisinin. Add a note on Artemisinin based Combination Therapy (ACT)

Reading File

Now let me search the medical library for anti-malarial drugs and artemisinin simultaneously.

Finding Sources

Excellent - found key sources. Now let me read the relevant sections from Goodman & Gilman, Katzung, and Lippincott simultaneously.

Reading File

Now let me get the full artemisinin section from Goodman & Gilman and also the classification of antimalarials from Katzung:

Reading File

I now have rich content from Goodman & Gilman and Katzung. Let me also get the classification section from Katzung and the ACT section from Goodman & Gilman:

Reading File

I now have excellent, comprehensive content from multiple authoritative sources. Let me compile the full answer.

Anti-Malarial Drugs

I. Classification

Anti-malarial drugs can be classified by several schemes - chemical class, stage of parasite life cycle targeted, and clinical use:

A. By Chemical Class

Class	Drugs
4-Aminoquinolines	Chloroquine, Hydroxychloroquine, Amodiaquine
8-Aminoquinolines	Primaquine, Tafenoquine
Quinoline-methanols	Quinine, Quinidine, Mefloquine
Sesquiterpene lactones (Artemisinins)	Artemisinin, Artesunate, Artemether, Dihydroartemisinin (DHA), Arteether
Antifolates	Pyrimethamine, Proguanil, Sulfadoxine (DHPS inhibitor), Cycloguanil
Napthoquinones	Atovaquone
Antibiotics	Doxycycline, Tetracycline, Clindamycin
Fixed combinations	Atovaquone-Proguanil (Malarone), Artemether-Lumefantrine (Coartem)

B. By Stage of Parasite Life Cycle Targeted

Stage	Drugs Active
Asexual blood (schizonticides)	Chloroquine, Quinine, Artemisinins, Mefloquine, Atovaquone-Proguanil, Sulfadoxine-Pyrimethamine
Tissue schizonticide (causal prophylaxis, liver stages)	Primaquine, Tafenoquine, Atovaquone-Proguanil
Hypnozoiticide (P. vivax/ovale relapse prevention)	Primaquine, Tafenoquine
Gametocytocidal	Primaquine (P. falciparum), Tafenoquine, Artemisinins (young gametocytes)
Sporontocidal	Primaquine, Pyrimethamine

C. By Clinical Use

Use	Drugs
Treatment of uncomplicated falciparum malaria	ACTs (Artemether-lumefantrine, Artesunate-amodiaquine, DHA-piperaquine), Atovaquone-proguanil
Severe/complicated malaria	IV Artesunate (first-line), IV Quinine
Chloroquine-sensitive malaria	Chloroquine (P. vivax, P. malariae)
Radical cure (P. vivax/ovale)	Chloroquine + Primaquine or Tafenoquine
Chemoprophylaxis	Chloroquine, Mefloquine, Doxycycline, Atovaquone-Proguanil

II. Artemisinin

Background

Artemisinin (qinghaosu) is a sesquiterpene lactone endoperoxide derived from the sweet wormwood plant Artemisia annua, used in traditional Chinese medicine for over 2000 years. Its discovery as a potent anti-malarial by Chinese scientist Tu Youyou earned the 2015 Nobel Prize in Medicine/Physiology. Key semisynthetic derivatives include:

Artesunate - water-soluble; oral, IV, IM, rectal
Artemether - lipid-soluble; oral, IM, rectal
Dihydroartemisinin (DHA) - water-soluble; oral (active metabolite of both)
Arteether - lipid-soluble; IM

Mechanism of Action (MoA)

The antimalarial action involves two linked steps:

Endoperoxide bridge activation: Inside the parasite's digestive vacuole, heme iron (released during hemoglobin digestion) cleaves the artemisinin endoperoxide bridge, generating highly reactive carbon-centered free radicals.
Alkylation and oxidation: These free radicals promiscuously alkylate and oxidize a wide variety of parasite proteins and macromolecules, causing widespread cellular damage.

Artemisinins act on asexual erythrocytic stages of all human malaria parasites - they are blood schizonticides with no activity on liver or sporozoite stages.
They are also active against young (but not mature) gametocytes of P. falciparum, which may reduce onward transmission.
They produce a 4-log10 reduction in parasite burden per 48-hour intraerythrocytic cycle, requiring 3-4 cycles (6-8 days) as monotherapy for complete parasite clearance.
Artemisinins are the fastest-acting antimalarials currently available.

(Goodman & Gilman's, p.1313; Katzung, p.1437)

Pharmacokinetics

Rapidly absorbed; peak plasma levels occur promptly after oral dosing
Oral bioavailability typically 30% or less
Short plasma half-life: DHA t₁/₂ ~1-2 hours
Both artesunate and artemether are metabolized to DHA (the active form)
Protein binding: 43-82%
With repeated dosing, artemisinin induces its own CYP-mediated metabolism (via CYP2B6 and CYP3A4), increasing clearance up to 5-fold
Short t₁/₂ makes them unsuitable for chemoprophylaxis

Adverse Effects

Artemisinins are generally well tolerated. Adverse effects include:

Adverse Effect	Details
Hematological	Dose-related, reversible decrease in reticulocyte and neutrophil counts; thrombocytopenia; hemolytic anemia (particularly post-artesunate hemolysis)
Hepatotoxicity	Elevated transaminases (reversible); hyperbilirubinemia
Neurotoxicity	Preclinical studies identified brain and brainstem as target organs; no systematic neurologic changes seen in patients ≥5 years in clinical settings
Embryotoxicity	Increased embryo lethality/malformations in rats and rabbits in early postconception period; ACTs not recommended in the first trimester or in children <5 kg
Allergic reactions	~1 in 3000 patients; hypersensitivity, rash
GI effects	Nausea, vomiting, diarrhea (particularly with artemether-lumefantrine)
Bone marrow	Identified as a target organ in preclinical studies

(Goodman & Gilman's, p.1313)

Therapeutic Uses

Severe/complicated P. falciparum malaria: IV artesunate is the drug of choice (FDA approved 2020). Large RCTs and meta-analyses show IV artesunate is superior to IV quinine for both parasite clearance time and patient survival, with a better safety profile.
Uncomplicated falciparum malaria: Used exclusively as ACT (see below) - never as monotherapy due to high recrudescence rates from short t₁/₂.
Multidrug-resistant P. falciparum: Artemisinins remain effective against chloroquine-sensitive and chloroquine-resistant strains.
P. vivax malaria: Effective against asexual erythrocytic stages; must be combined with primaquine/tafenoquine for radical cure of liver hypnozoites.
Gametocyte carriage reduction: Decreases gametocyte carriage, potentially reducing transmission.

Artemisinins are not used for prophylaxis due to their very short half-lives.

III. Note on Artemisinin-Based Combination Therapy (ACT)

Rationale for ACT

ACT is the WHO-recommended standard of care for uncomplicated falciparum malaria globally. The rationale for combining artemisinins with a partner drug is:

Short t₁/₂ of artemisinins: When given alone, 7+ days of therapy are needed to fully eliminate parasites (recrudescence is common with shorter courses). A partner drug with a longer t₁/₂ "covers" the tail period after the artemisinin is eliminated.
Prevention of resistance: Combining two drugs with distinct mechanisms protects each drug from resistance selection. Monotherapy is strongly discouraged by the WHO.
Synergistic efficacy: The rapid-acting artemisinin dramatically reduces parasite burden within the first 24-48 hours, allowing the slower-acting partner to mop up remaining parasites.

WHO-Recommended ACT Regimens

Regimen	Route	Key Notes
Artemether-lumefantrine (Coartem)	Oral	Only ACT FDA-approved in USA; first-line across Africa; must be taken with fatty food
Artesunate-amodiaquine (ASAQ, Coarsucam)	Oral	First-line in many African countries
Artesunate-mefloquine	Oral	First-line in parts of SE Asia and South America
Dihydroartemisinin-piperaquine (Artekin, Duocotecxin)	Oral	First-line in some SE Asian countries; longest post-treatment prophylaxis (piperaquine t₁/₂ ~28 days)
Artesunate-pyronaridine (Pyramax)	Oral	Efficacy similar to other ACTs
Artesunate-sulfadoxine-pyrimethamine	Oral	First-line in some areas; limited by SP resistance

(Katzung Table 52-4, p.1435; Goodman & Gilman's, p.1314)

ACT in Special Situations

Severe malaria: IV artesunate for initial treatment, followed by completion of oral ACT
Pregnancy (1st trimester): ACTs generally avoided; accumulating evidence for artemether-lumefantrine safety may change this
P. vivax/ovale: ACT addresses blood stages; must add primaquine or tafenoquine for liver stages
Resistance concerns: Delayed clearance of P. falciparum after artemisinin therapy - initially in SE Asia, now identified in East Africa - is a serious public health threat. Decreased efficacy of artesunate-mefloquine and DHA-piperaquine in SE Asia has been reported.

Partner Drug Profiles

Lumefantrine: t₁/₂ 4-5 days; structurally similar to mefloquine/halofantrine; absorption markedly increased with high-fat food
Amodiaquine: t₁/₂ ~14 days; 4-aminoquinoline class
Mefloquine: t₁/₂ ~14 days; relatively poor tolerability limits wider use
Piperaquine: t₁/₂ ~28 days (longest); bisquinoline; provides extended post-treatment prophylaxis

Sources:

Goodman & Gilman's The Pharmacological Basis of Therapeutics, pp.1312-1314 (Artemisinin and Its Derivatives)
Katzung's Basic and Clinical Pharmacology, 16th ed., pp.1434-1438 (ARTEMISININ & ITS DERIVATIVES, ACT tables)
Lippincott Illustrated Reviews: Pharmacology, pp.1174-1176 (G. Artemisinin)

This is a shared conversation. Sign in to Orris to start your own chat.